| 000 | 05440nam a22006375i 4500 | ||
|---|---|---|---|
| 001 | 978-1-0716-3774-6 | ||
| 003 | DE-He213 | ||
| 005 | 20260610083714.0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 240301s2024 xxu| s |||| 0|eng d | ||
| 020 |
_a9781071637746 _9978-1-0716-3774-6 |
||
| 024 | 7 |
_a10.1007/978-1-0716-3774-6 _2doi |
|
| 050 | 4 | _aQH438.4.B55 | |
| 050 | 4 | _aR853.B54 | |
| 072 | 7 |
_aMBGR _2bicssc |
|
| 072 | 7 |
_aMED106000 _2bisacsh |
|
| 072 | 7 |
_aMBGR _2thema |
|
| 082 | 0 | 4 |
_a610.72 _223 |
| 245 | 1 | 0 |
_aBiomarkers for Alzheimer’s Disease Drug Development _h[electronic resource] / _cedited by Robert Perneczky. |
| 250 | _a2nd ed. 2024. | ||
| 264 | 1 |
_aNew York, NY : _bSpringer US : _bImprint: Humana, _c2024. |
|
| 300 |
_aXII, 347 p. 51 illus., 49 illus. in color. _bonline resource. |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 341 | 0 |
_bTable of contents navigation _2onix |
|
| 341 | 0 |
_bSingle logical reading order _2onix |
|
| 341 | 0 |
_bShort alternative textual descriptions _2onix |
|
| 341 | 0 |
_bUse of color is not sole means of conveying information _2onix |
|
| 341 | 0 |
_bUse of high contrast between text and background color _2onix |
|
| 341 | 0 |
_bNext / Previous structural navigation _2onix |
|
| 341 | 0 |
_bAll non-decorative content supports reading without sight _2onix |
|
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 1 |
_aMethods in Molecular Biology, _x1940-6029 ; _v2785 |
|
| 505 | 0 | _aBlood-Based Biomarkers for Early Alzheimer’s Disease Diagnosis in Real-World Settings -- Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approaches -- CSF N-Glycomics Using High Throughput UPLC-ESI Techniques in Alzheimer’s Disease -- CSF N-Glycomics Using MALDI MS Techniques -- Optimized Pre-Analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Disease -- Mass Spectrometry-Based Metabolomics Multi-Platform for Alzheimer’s Disease Research -- Analysis of Resting-State Functional Magnetic Resonance Imaging in Alzheimer's Disease -- Diffusion Tensor Imaging in Alzheimer’s Studies -- Magnetic Resonance Spectroscopy (MRS) in Alzheimer’s Disease -- Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies -- Amyloid PET Imaging: Standard Procedures and Semiquantification -- PET Imaging to Measure Neuroinflammation In Vivo -- Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach -- High-Throughput Lipidomics and Metabolomics Profiling for Brain Tissue and Biofluid Samples in Neurodegenerative Disorders -- Neuropathological Assessment as an Endpoint in Clinical Trial Design -- Non-Invasive Visualization of Amyloid-Beta Deposits in Alzheimer’s Amyloidosis Mice via Fluorescence Molecular Tomography Using Contrast Agent -- Brain Banking in Dementia Studies -- Speech-Based Digital Biomarkers for Alzheimer’s Research -- cCOG Web-Based Cognitive Assessment Tool -- In Silico Models to Validate Novel Blood-Based Biomarkers. | |
| 520 | _aThis fully updated volume provides an up-to-date and comprehensive overview of the current state of technologies helping to accelerate Alzheimer’s disease drug development. Addressing the latest advances in preclinical and clinical research, including new insights into the molecular mechanisms and emerging therapeutic strategies, the book continues by exploring digital biomarkers and advanced neuroimaging analysis which will transform how clinical trials in the Alzheimer’s disease field are performed. Written for the highly successful Methods in Molecular Biology series, chapters feature the kind of detailed implementation advice that leads to greater success in the lab or clinic. Authoritative and practical, Biomarkers for Alzheimer’s Disease Drug Development, Second Edition seeks to inspire and inform future efforts to develop effective treatments for this devastating disease. | ||
| 532 | 8 | _aAccessibility summary: This PDF does not fully comply with PDF/UA standards, but does feature limited screen reader support, described non-text content (images, graphs), bookmarks for easy navigation and searchable, selectable text. Users of assistive technologies may experience difficulty navigating or interpreting content in this document. We recognize the importance of accessibility, and we welcome queries about accessibility for any of our products. If you have a question or an access need, please get in touch with us at accessibilitysupport@springernature.com. | |
| 532 | 8 | _aNo reading system accessibility options actively disabled | |
| 532 | 8 | _aPublisher contact for further accessibility information: accessibilitysupport@springernature.com | |
| 650 | 0 | _aBiochemical markers. | |
| 650 | 0 | _aNeuropharmacology. | |
| 650 | 0 |
_aNervous system _xDiseases. |
|
| 650 | 1 | 4 | _aBiomarkers. |
| 650 | 2 | 4 | _aNeuropharmacology. |
| 650 | 2 | 4 | _aNeurological Disorders. |
| 700 | 1 |
_aPerneczky, Robert. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt |
|
| 710 | 2 | _aSpringerLink (Online service) | |
| 773 | 0 | _tSpringer Nature eBook | |
| 776 | 0 | 8 |
_iPrinted edition: _z9781071637739 |
| 776 | 0 | 8 |
_iPrinted edition: _z9781071637753 |
| 776 | 0 | 8 |
_iPrinted edition: _z9781071637760 |
| 830 | 0 |
_aMethods in Molecular Biology, _x1940-6029 ; _v2785 |
|
| 856 | 4 | 0 | _uhttps://doi.org/10.1007/978-1-0716-3774-6 |
| 912 | _aZDB-2-PRO | ||
| 999 |
_c8046 _d8046 |
||